Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTIVATE study of claseprubart in adults with CIDP
NL-OMON60638Phase 3Not yet recruiting
- Sponsor
- Dianthus Therapeutics
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (4 arms), sponsored by Dianthus Therapeutics. Primary endpoint: Time to relapse. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
claseprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON60638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60638.